Treatment of early tongue carcinoma with brachytherapy

Results over a 25-year period

Yusuke Urashima, Katsumasa Nakamura, Yoshiyuki Shioyama, Satoru Nomoto, Ohga Saiji, Takashi Toba, Tadamasa Yoshitake, Toru Chikui, Toshiyuki Kawazu, Kenichi Jingu, Hiromi Terashima, Hiroshi Honda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Brachytherapy for patients with early tongue cancer is an accepted method of treatment. Patients and Methods: The records of 409 patients with T1/2N0M0 tongue cancer treated with brachytherapy between 1978 and 2004 were reviewed. Results: The overall and disease-free 5-year survival rates were 82.3% and 64.6% for patients with T1 disease, and 72.2% and 56.0% for patients with T2 disease, respectively. The 5-year nodal metastasis-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 64.8%, 74.8% and 81.3% for patients with T1 disease (p=0.22), and 47.4%, 70.4% and 76.4% for patients with T2 disease (p=0.0011), respectively. The 5-year local recurrence-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 91.0%, 84.0% and 96.9% for patients with T1 disease (p=0.31), and 87.6%, 83.3% and 85.8% for patients with T2 disease (p=0.90), respectively. Conclusion: The incidence rate of nodal metastasis in patients with early tongue cancer improved over the 25-year period studied, while the local recurrence-free survival rates remained stable.

Original languageEnglish
Pages (from-to)3519-3523
Number of pages5
JournalAnticancer Research
Volume27
Issue number5 B
Publication statusPublished - Sep 2007

Fingerprint

Brachytherapy
Tongue
Carcinoma
Tongue Neoplasms
Therapeutics
Survival Rate
Neoplasm Metastasis
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Urashima, Y., Nakamura, K., Shioyama, Y., Nomoto, S., Saiji, O., Toba, T., ... Honda, H. (2007). Treatment of early tongue carcinoma with brachytherapy: Results over a 25-year period. Anticancer Research, 27(5 B), 3519-3523.

Treatment of early tongue carcinoma with brachytherapy : Results over a 25-year period. / Urashima, Yusuke; Nakamura, Katsumasa; Shioyama, Yoshiyuki; Nomoto, Satoru; Saiji, Ohga; Toba, Takashi; Yoshitake, Tadamasa; Chikui, Toru; Kawazu, Toshiyuki; Jingu, Kenichi; Terashima, Hiromi; Honda, Hiroshi.

In: Anticancer Research, Vol. 27, No. 5 B, 09.2007, p. 3519-3523.

Research output: Contribution to journalArticle

Urashima, Y, Nakamura, K, Shioyama, Y, Nomoto, S, Saiji, O, Toba, T, Yoshitake, T, Chikui, T, Kawazu, T, Jingu, K, Terashima, H & Honda, H 2007, 'Treatment of early tongue carcinoma with brachytherapy: Results over a 25-year period', Anticancer Research, vol. 27, no. 5 B, pp. 3519-3523.
Urashima Y, Nakamura K, Shioyama Y, Nomoto S, Saiji O, Toba T et al. Treatment of early tongue carcinoma with brachytherapy: Results over a 25-year period. Anticancer Research. 2007 Sep;27(5 B):3519-3523.
Urashima, Yusuke ; Nakamura, Katsumasa ; Shioyama, Yoshiyuki ; Nomoto, Satoru ; Saiji, Ohga ; Toba, Takashi ; Yoshitake, Tadamasa ; Chikui, Toru ; Kawazu, Toshiyuki ; Jingu, Kenichi ; Terashima, Hiromi ; Honda, Hiroshi. / Treatment of early tongue carcinoma with brachytherapy : Results over a 25-year period. In: Anticancer Research. 2007 ; Vol. 27, No. 5 B. pp. 3519-3523.
@article{f30a1e4a3fce41da8fbef969f1ac64bc,
title = "Treatment of early tongue carcinoma with brachytherapy: Results over a 25-year period",
abstract = "Background: Brachytherapy for patients with early tongue cancer is an accepted method of treatment. Patients and Methods: The records of 409 patients with T1/2N0M0 tongue cancer treated with brachytherapy between 1978 and 2004 were reviewed. Results: The overall and disease-free 5-year survival rates were 82.3{\%} and 64.6{\%} for patients with T1 disease, and 72.2{\%} and 56.0{\%} for patients with T2 disease, respectively. The 5-year nodal metastasis-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 64.8{\%}, 74.8{\%} and 81.3{\%} for patients with T1 disease (p=0.22), and 47.4{\%}, 70.4{\%} and 76.4{\%} for patients with T2 disease (p=0.0011), respectively. The 5-year local recurrence-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 91.0{\%}, 84.0{\%} and 96.9{\%} for patients with T1 disease (p=0.31), and 87.6{\%}, 83.3{\%} and 85.8{\%} for patients with T2 disease (p=0.90), respectively. Conclusion: The incidence rate of nodal metastasis in patients with early tongue cancer improved over the 25-year period studied, while the local recurrence-free survival rates remained stable.",
author = "Yusuke Urashima and Katsumasa Nakamura and Yoshiyuki Shioyama and Satoru Nomoto and Ohga Saiji and Takashi Toba and Tadamasa Yoshitake and Toru Chikui and Toshiyuki Kawazu and Kenichi Jingu and Hiromi Terashima and Hiroshi Honda",
year = "2007",
month = "9",
language = "English",
volume = "27",
pages = "3519--3523",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - Treatment of early tongue carcinoma with brachytherapy

T2 - Results over a 25-year period

AU - Urashima, Yusuke

AU - Nakamura, Katsumasa

AU - Shioyama, Yoshiyuki

AU - Nomoto, Satoru

AU - Saiji, Ohga

AU - Toba, Takashi

AU - Yoshitake, Tadamasa

AU - Chikui, Toru

AU - Kawazu, Toshiyuki

AU - Jingu, Kenichi

AU - Terashima, Hiromi

AU - Honda, Hiroshi

PY - 2007/9

Y1 - 2007/9

N2 - Background: Brachytherapy for patients with early tongue cancer is an accepted method of treatment. Patients and Methods: The records of 409 patients with T1/2N0M0 tongue cancer treated with brachytherapy between 1978 and 2004 were reviewed. Results: The overall and disease-free 5-year survival rates were 82.3% and 64.6% for patients with T1 disease, and 72.2% and 56.0% for patients with T2 disease, respectively. The 5-year nodal metastasis-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 64.8%, 74.8% and 81.3% for patients with T1 disease (p=0.22), and 47.4%, 70.4% and 76.4% for patients with T2 disease (p=0.0011), respectively. The 5-year local recurrence-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 91.0%, 84.0% and 96.9% for patients with T1 disease (p=0.31), and 87.6%, 83.3% and 85.8% for patients with T2 disease (p=0.90), respectively. Conclusion: The incidence rate of nodal metastasis in patients with early tongue cancer improved over the 25-year period studied, while the local recurrence-free survival rates remained stable.

AB - Background: Brachytherapy for patients with early tongue cancer is an accepted method of treatment. Patients and Methods: The records of 409 patients with T1/2N0M0 tongue cancer treated with brachytherapy between 1978 and 2004 were reviewed. Results: The overall and disease-free 5-year survival rates were 82.3% and 64.6% for patients with T1 disease, and 72.2% and 56.0% for patients with T2 disease, respectively. The 5-year nodal metastasis-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 64.8%, 74.8% and 81.3% for patients with T1 disease (p=0.22), and 47.4%, 70.4% and 76.4% for patients with T2 disease (p=0.0011), respectively. The 5-year local recurrence-free survival rates for patients treated between 1978 and 1986, 1987 and 1996, and 1997 and 2004 were 91.0%, 84.0% and 96.9% for patients with T1 disease (p=0.31), and 87.6%, 83.3% and 85.8% for patients with T2 disease (p=0.90), respectively. Conclusion: The incidence rate of nodal metastasis in patients with early tongue cancer improved over the 25-year period studied, while the local recurrence-free survival rates remained stable.

UR - http://www.scopus.com/inward/record.url?scp=35348948489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348948489&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 3519

EP - 3523

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -